118 results on '"Stargardt, Tom"'
Search Results
2. Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO‐ASSIST study)
3. From Health to Wellbeing:Toward a Monetary Valuation of a Wellbeing-Adjusted Life-Year
4. Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO‐ASSIST study).
5. Cooperation Improvement in an Integrated Healthcare Network: A Social Network Analysis
6. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
7. Vaccine hesitancy comes in waves:Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries
8. Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries
9. Braving the waves:exploring capability well-being patterns in seven European countries during the COVID-19 pandemic
10. Health-related quality of life in seven European countries throughout the course of the COVID-19 pandemic:evidence from the European COvid Survey (ECOS)
11. Cost-utility analysis of early versus delayed endovascular intervention in critical limb-threatening ischemia patients with rest pain
12. Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries
13. Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting
14. Effectiveness of a home telemonitoring program for patients with chronic obstructive pulmonary disease in Germany: Evidence from the first three years
15. Prevalence and determinants of probable depression and anxiety during the COVID-19 pandemic in seven countries:Longitudinal evidence from the European COvid Survey (ECOS)
16. Depression and anxiety in later COVID-19 waves across Europe:New evidence from the European COvid Survey (ECOS)
17. Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting.
18. Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching
19. Reimbursement of Pharmaceuticals: reference pricing versus health technology assessment
20. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
21. Determining the "Health Benefit Basket" of the Statutory Health Insurance Scheme in Germany: Methodologies and Criteria
22. Risk communication during COVID-19
23. Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes
24. Risk communication during COVID-19: A descriptive study on familiarity with, adherence to and trust in the WHO preventive measures
25. Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study
26. Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
27. The Trade-Off between Costs and Outcomes: The Case of Acute Myocardial Infarction
28. The impact of mode of drug administration on medication adherence
29. Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes
30. Measuring the relationship between costs and outcomes: The example of Acute Myocardial Infarction in German hospitals
31. Effect of type of insurance and income on waiting time for outpatient care
32. Defining benefit catalogues and entitlements to health care in Germany: Decision makers, decision criteria and taxonomy of catalogues
33. Bürgerversicherung: Die Wirkung von Kopfprämien auf den Arbeitsmarkt
34. The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study
35. The impact of partnership network stability on new product development cost in the pharmaceutical industry
36. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
37. Cost of illness and economic burden of chronic lymphocytic leukemia
38. Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching
39. Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer
40. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
41. Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
42. Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes
43. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
44. Determining the 'Health Benefit Basket' of the Statutory Health Insurance scheme in Germany
45. Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study
46. The impact of mode of drug administration on medication adherence
47. Real-World Evidence of User Engagement With Mobile Health for Diabetes Management: Longitudinal Observational Study
48. Countering COVID 19: A European survey on acceptability of and commitment to preventive measures
49. Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK
50. The impact of mode of drug administration on medication adherence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.